GNPX:NASDAQGenprex, Inc. Analysis

Genprex, Inc. (GNPX) trades at $5.99, a level dramatically below its 20‑day ($9.30), 50‑day ($12.08) and 200‑day ($56.35) simple moving averages, signaling a deep, sustained bearish trend. The RSI of 29 indicates oversold conditions, yet the MACD remains bearish and volume is declining, reinforcing short‑term downside pressure. The company holds $18 M in cash but generates no revenue, has negative operating and free cash flow, and reports a trailing EPS of –$111.32, underscoring a cash‑burning, pre‑revenue profile. On the bright side, the stock’s price‑to‑book ratio of 0.15 suggests a substantial discount to its $41.18 book value per share, and recent patent allowance news for a combination therapy could serve as a catalyst if clinical data materialize. However, extreme 30‑day volatility (≈150%), a beta of 2.25, and a historic max drawdown of –99% highlight the speculative nature of the investment.
Given the confluence of technical weakness, absent earnings, and high sector‑specific regulatory risk, the stock is best viewed as a high‑risk, deep‑value play that may only reward investors with a long‑term horizon and tolerance for binary outcomes.